| 16001/34347 | US=22 / Urologia Hutson TE, Thakkar S, Cohen P, Borden EC. Interferons and interleukin-2: molecular basis of activity and therapeutic results. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 49-78. ISBN 978-1-58829-737-2. INTERFERON; INTERLEUCINA; IFN-X2, IL-2; INIBICAO DA ANGIOGENESE; EFEITOS CLINICOS DA IL-2 E IFN |
| 16002/34347 | US=22 / Urologia Junior Kaelin WG, Geoge DJ. The molecular biology of kidney cancer and its clinical translation into treatment strategies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 79-97. ISBN 978-1-58829-737-2. VON HIPPEL-LINDAU; HIPOXIA; ANGIOGENESE; HIF; VEGF; KDR; MTOR |
| 16003/34347 | US=22 / Urologia Rathmell WK, Rini BI. VEGF: biologic aspects and clinical approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 99-118. ISBN 978-1-58829-737-2. |
| 16004/34347 | US=22 / Urologia Lam JS, Figlin RA, Belldegrum AS,. VEGF: and PDGF receptors: biologic relevance and clinical approaches to inhibition. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 119-49. ISBN 978-1-58829-737-2. DERIVADO DE PLAQUETAS FACTOR DE CRESCIMENTO; RECEPTORES; TRANSDUCAO DE SINAL; TIROSINA-QUINASE; FACTOR DE CRESCIMENTO ENDOTELIAL VASCULAR |
| 16005/34347 | US=22 / Urologia Motzer RJ. Sunitinib and axitinib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 151-65. ISBN 978-1-58829-737-2. SUNITINIB; SU11248; AXITINIBE; CARCINOMA DE CELULAS RENAIS; SUTENT; AG-013736 |
| 16006/34347 | US=22 / Urologia George S, Bukowski RM. Sorafenib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 167-87. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; SORAFENIB; INIBIDOR DE TIROSINA CINASE; VEGF; TERAPIA ANTIANGIOGENICA |
| 16007/34347 | US=22 / Urologia Rini BI. Additional tyrosine kinase inhibitors in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 189-93. ISBN 978-1-58829-737-2. INIBIDORES VEGF; TKI; PTK787; AZD2171; ZK222584; INIBIDOR DE TIROSINA CINASE; PAZOPANIB |
| 16008/34347 | US=22 / Urologia Ramakrishnan V, Bhaskar V, Fox M, Wilson K, Cheville JC, Finck BA. Integrin &*945;5&*946;1 as a noveltherapeutic target in renal cancer. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 195-209. ISBN 978-1-58829-737-2. INTEGRINAS NA ANGIOGENESE; TERAPIA ANTI-ANGIOGENICA; CANCER RENAL &*945;5&*946;1; VOLOCIXIMAB |
| 16009/34347 | US=22 / Urologia Shuch B, Belldegrun AS, Figlin RA. Carbonic anhydrase IX: biology and clinical approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 211-29. ISBN 978-1-58829-737-2. CAIX; CCR CELULA CLARA; INTERLEUCINA-2 RESPOSTA; PROGNOSTICO; G250 |
| 16010/34347 | US=22 / Urologia Oosterwijk-Wakka JC, Boerman OC, Mulders PFA, Oosterwijk E. Monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma: biological and clinical studies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 231-47. ISBN 978-1-58829-737-2. |
| 16011/34347 | US=22 / Urologia Reckamp KL, Figlin RA, Strieter RM. Chemokines in renal cell carcinoma: implications for tumor angiogenesis and metastasis. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 249-65. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; QUIMIOCINAS; ANGIOGENESE; POTENCIAL METASTATICO; TRATAMENTO |
| 16012/34347 | US=22 / Urologia Cho D, Mier JW, Atkins MB. PI3K/AKt/mTOR pathway: a growth and proliferation pathway. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 267-85. ISBN 978-1-58829-737-2. INIBIDORES PI3K; RCC; HIPERATIVACAO DO AKT/PI3K; ATIVIDADE AKT; TEMSIROLIMUS |
| 16013/34347 | US=22 / Urologia Jonasch E, Walker CL. EGFR and HER2: relevance in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 287-303. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; ERBB; TERAPIA-ALVO; RESISTENCIA; SINALIZACAO |
| 16014/34347 | US=22 / Urologia Garcia JA, Varizi SJA, Ganapathi R. Proteasome-NFkB signaling pathway: relevance in RCC. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 305-20. ISBN 978-1-58829-737-2. SISTEMA UBIQUITINA-PROTEASSOMA; VIA DE PROTEASSOMA NA RCC; INIBICAO DO PROTEASSOMA |
| 16015/34347 | US=22 / Urologia Peruzzi B, Lattouf JB, Bottaro DP. The role of hepatocyte growth factor pathway signaling in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 321-34. ISBN 978-1-58829-737-2. FATOR DE CRESCIMENTO HEPATOCITO; C-MET; CARCINOMA DE CELULAS RENAIS; MECANISMOS ONCOGENICOS; DESENVOLVIMENTO DROGA CONTRA O CANCER |
| 16016/34347 | US=22 / Urologia Mizutani Y, kawauchi A, Bonavida B, Miki T. Smac/DIABLO: a proapoptotic molecular target in renal cell cancer. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 335-46. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; SMAC / DIABLO; PROGNOSTICO; APOPTOSE; CISPLATINA; XIAP; RCC; TRAIL |
| 16017/34347 | US=22 / Urologia Kawabe M, Herrem CJ, Finke JH, Storkus WJ. EphA2: a novel target in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 347-66. ISBN 978-1-58829-737-2. RTK; CD8+ T LINFOCITOS; QUINASE DE TIROSINA RECEPTORA; PROTEASSOMA; TERAPIA COMBINATORIA; COMPLEXO PRINCIPAL DE HISTOCOMPATIBILIDADE |
| 16018/34347 | US=22 / Urologia Inman BA, Frigola X, Dong H, Yang JC, Kwon ED. Restoring host antitumoral immunity: how coregulatory molecules are changing the approach to the management of renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 367-403. ISBN 978-1-58829-737-2. COESTIMULACAO; INIBICAO; IMUNOLOGIA DE TUMORES; IMMUNOEDITING; IMUNOTERAPIA; LINFOCITOS T; CARCINOMA DE CELULAS RENAIS |
| 16019/34347 | US=22 / Urologia Shaheen PE, Bukowski RM, Finke JH. The role of gangliosides in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 405-23. ISBN 978-1-58829-737-2. GANGLIOSIDEOS NA RCC; GLICOESFINGOLIPIDOS; GANGLIOSIDOS E VEGF; GANGLIOSIDEOS COMO ALVOS TERAPEUTICOS |
| 16020/34347 | US=22 / Urologia Parton M, Das T, Sa G, Finke J, Eisen T, Tannenbaum C. Tumour necrosis factor - misnomer and therapeutic target. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 425-48. ISBN 978-1-58829-737-2. FATOR DE NECROSE TUMORAL; CITOCINA; IMUNOMODULACAO; ANGIOGENESE; FATOR DE CRESCIMENTO |